Bill is the Chief Corporate Affairs Officer of Neumora, where his responsibilities include medical affairs, professional relations and patient advocacy. He brings to Neumora deep expertise in global medical affairs and corporate strategy, as well as a demonstrated track record of success in launching over 12 products across biologics and small molecules, and therapeutic areas including neuropsychiatry, oncology, rheumatology, dermatology and nephrology.
Before Neumora, Bill was the chief scientific affairs officer of Dermira, Inc., where he built the company’s medical affairs function and played a central role in the Roche-Genentech’s transaction to obtain worldwide rights to lebrikizumab, as well as Dermira’s acquisition by Eli Lilly and Company for $1.1 billion. Previously, he held vice president roles in medical affairs at Neurocrine Biosciences and global scientific affairs at both Merck Research Laboratories and Amgen.
Bill holds a Pharm.D. from the University of Texas Health Science Center, San Antonio, and B.S. in pharmacy from the University of Texas at Austin. He obtained board certification in psychiatric pharmacy practice.